Author details

Full Name

David C Montefiori

Affiliation

ORCID

Career Start Year

1979

Papers

900

H Index

123

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36845143	Mid-titer human convalescent plasma administration results in suboptimal prophylaxis against SARS-CoV-2 infection in rhesus macaques.		2023
36348617	Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.	Journal of Infectious Diseases	2023
35860221	Mapping SARS-CoV-2 antigenic relationships and serological responses.	bioRxiv	2023
37679276	Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.		2023
38036525	Engineered immunogens to elicit antibodies against conserved coronavirus epitopes.	Nat Commun	2023
37925510	A combined adjuvant approach primes robust germinal center responses and humoral immunity in non-human primates.		2023
37824545	Correction: HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.		2023
37820782	Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial.		2023
37653342	Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.		2023
38005994	In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4 T-Cells.		2023
37808679	Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera.	bioRxiv	2023
37802566	Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 ran		2023
37645950	Mutational basis of serum cross-neutralization profiles elicited by infection or vaccination with SARS-CoV-2 variants.		2023
37986885	Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques.	bioRxiv	2023
37896806	Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial.		2023
38085509	Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines.		2023
37886518	Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains.		2023
37797027	Mapping SARS-CoV-2 antigenic relationships and serological responses.	Science	2023
37561027	Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.	J Infect Dis	2023
37874153	Host immunity associated with spontaneous suppression of viremia in therapy-naÃ¯ve young rhesus macaques following neonatal SHIV infection.		2023
37553348	Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques.	Nat Commun	2023
37612300	Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.		2023
37034641	Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.	medRxiv	2023
36909627	Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes.	bioRxiv	2023
36717721	Author Correction: Long-primed germinal centres with enduring affinity maturation and clonal migration.		2023
37205592	Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial.	Res Sq	2023
37330602	Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.		2023
37075127	Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial.	Sci Transl Med	2023
36882405	Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251.		2023
37256916	Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.		2023
36629414	A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies.	mBio	2023
37384759	Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.		2023
36935288	Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.	Vaccine	2023
37300931	Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition.	EBioMedicine	2023
37425865	Focusing antibody responses to the fusion peptide in rhesus macaques.		2023
37044090	Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.	Cell Rep Med	2023
36924501	Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies.		2023
36732510	HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC.	Nat Commun	2023
36787249	Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.		2023
36454813	Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later.	Sci Transl Med	2023
37036397	Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.	Clin Infect Dis	2023
35241844	Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.	Nature Medicine	2022
36112399	A Bivalent Omicron-Containing Booster Vaccine against Covid-19.	New England Journal of Medicine	2022
35709309	Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4.	PLoS Pathogens	2022
35584627	Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody.	Cell Reports Medicine	2022
35898343	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses.	medRxiv	2022
35449174	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers.	npj Vaccines	2022
35759252	Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals.	Journal of Infectious Diseases	2022
35507661	Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain.	Science advances	2022
35951767	An antibody from single human V<sub>H</sub>-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion.	Sci Immunol	2022